Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Adams

Showing results (71-80 of 251) with videos related to

Pageof 26
Sort By:
Annals of Hematology|September 9, 2016
No convincing evidence to support postinduction FDG-PET in follicular lymphomaHugo J A Adams, Thomas C Kwee
Seminars in Oncology|June 25, 2018
An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphomaHugo J A Adams, Thomas C Kwee
Blood|June 3, 2018
Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been provenHugo J A Adams, Thomas C Kwee
Nuclear Medicine Communications|August 9, 2016
Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?Hugo J A Adams, Thomas C Kwee
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin LymphomaHugo J A Adams, Thomas C Kwee,
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
The predictive value of interim FDG-PET in early-stage Hodgkin lymphoma is not well establishedH J A Adams, T C Kwee
European Journal of Haematology|August 17, 2016
Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2015
Diffusion-weighted MRI for lymphoma staging--letterHugo J A Adams, Thomas C Kwee
Nuclear Medicine Communications|December 24, 2015
18F-FDG-PET is not a useful tool for end-of-treatment response evaluation in peripheral T-cell lymphomasHugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment in Advanced-Stage Hodgkin LymphomaHugo J A Adams, Thomas C Kwee
Pageof 26

Showing results (71-80 of 251) with videos related to

Sort By:
Pageof 26
Annals of Hematology|September 9, 2016
No convincing evidence to support postinduction FDG-PET in follicular lymphomaHugo J A Adams, Thomas C Kwee
Seminars in Oncology|June 25, 2018
An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphomaHugo J A Adams, Thomas C Kwee
Blood|June 3, 2018
Benefit of brentuximab over bleomycin in first-line treatment of advanced-stage Hodgkin lymphoma has not been provenHugo J A Adams, Thomas C Kwee
Nuclear Medicine Communications|August 9, 2016
Does interim 18F-FDG-PET response-adapted therapy really benefit advanced-stage Hodgkin lymphoma patients?Hugo J A Adams, Thomas C Kwee
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
Letter to the Editor: No Evidence to Promote Interim FDG-PET Adapted Therapy in the NCCN Guidelines for Hodgkin LymphomaHugo J A Adams, Thomas C Kwee,
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
The predictive value of interim FDG-PET in early-stage Hodgkin lymphoma is not well establishedH J A Adams, T C Kwee
European Journal of Haematology|August 17, 2016
Controversies on the prognostic value of interim FDG-PET in advanced-stage Hodgkin lymphomaHugo J A Adams, Thomas C Kwee
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2015
Diffusion-weighted MRI for lymphoma staging--letterHugo J A Adams, Thomas C Kwee
Nuclear Medicine Communications|December 24, 2015
18F-FDG-PET is not a useful tool for end-of-treatment response evaluation in peripheral T-cell lymphomasHugo J A Adams, Thomas C Kwee
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2018
Strikingly Heterogeneous Results Among Studies on Interim Fluorodeoxyglucose-Positron Emission Tomography-Adapted Treatment in Advanced-Stage Hodgkin LymphomaHugo J A Adams, Thomas C Kwee
Pageof 26